Our proprietary technology increases the quality, speed and overall efficiency of drug discovery by generating compound selectivity information against thousands of targets within key protein families. We profile individual compounds and compound libraries, without modifications or tags, simultaneously against thousands of native proteins from virtually any tissue or cell source.  Our technology creates economic value across the entire spectrum of drug discovery by dramatically improving targeted library screening, mechanism of action determination and toxicity testing, lead optimization and candidate selection.

Our technology is elegant and yet extremely powerful. By using a proprietary matrix, or affinity media, we reversibly capture purine-binding proteins from any tissue source. We then profile compounds against the affinity media to which the proteins are bound so that each compound competes with the affinity media for the protein binding sites. Only those proteins that have a binding affinity for each compound are eluted from the media, collected and identified.  In essence, we can search through the thousands of proteins in a particular tissue and very rapidly identify only the few protein targets to which a particular compound has affinity.